Is intravitreal bevacizumab an effective treatment option for nonarteritic anterior ischemic optic neuropathy?

Christina Rapp Prescott, Craig A. Sklar, Robert L. Lesser, Ron A. Adelman

Research output: Contribution to journalArticlepeer-review

Abstract

Nonarteritic anterior ischemic optic neuropathy (NAION) causes sudden profound loss of vision with no known cause or cure. Various treatment modalities, both surgical and pharmacologic, have been tried without success. The purpose of our retrospective study was to evaluate the effect of intravitreal bevacizumab (Avastin) as a treatment option for NAION. We evaluated demographics of 5 patients and compared visual acuity and automated visual fields prior to and following intravitreal bevacizumab injection. Visual acuity at presentation was 20/20 in 4 of 5 patients and 20/150 in 1. Visual acuity improved to 20/40 in the patient who presented with decreased acuity and decreased slowly in 3 patients and rapidly in 1. All patients presented with variable visual field defects: 1 improved slightly, 3 progressed, and 1 remained stable. One patient subsequently developed NAION in the fellow eye. These results are consistent with the natural course of the disease, and bevacizumab did not appear to have a dramatic effect on the clinical outcome in this small series of patients with NAION.

Original languageEnglish (US)
Pages (from-to)51-53
Number of pages3
JournalJournal of Neuro-Ophthalmology
Volume32
Issue number1
DOIs
StatePublished - Mar 1 2012
Externally publishedYes

ASJC Scopus subject areas

  • Ophthalmology
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Is intravitreal bevacizumab an effective treatment option for nonarteritic anterior ischemic optic neuropathy?'. Together they form a unique fingerprint.

Cite this